Scott Dreyer's most recent trade in Collegium Pharmaceutical Inc was a trade of 46,417 Common Stock done at an average price of $40.4 . Disclosure was reported to the exchange on March 3, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 40.36 per share. | 03 Mar 2026 | 46,417 | 75,329 (0%) | 0% | 40.4 | 1,873,557 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 40.99 per share. | 03 Mar 2026 | 3,559 | 71,770 (0%) | 0% | 41.0 | 145,879 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2026 | 30,702 | 153,338 (0%) | 0% | 0 | Common Stock | |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.75 per share. | 10 Feb 2026 | 21,615 | 121,746 (0%) | 0% | 46.7 | 1,010,501 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2026 | 19,023 | 122,636 (0%) | 0% | 0 | Common Stock | |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.75 per share. | 10 Feb 2026 | 9,977 | 143,361 (0%) | 0% | 46.8 | 466,425 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2025 | 17,600 | 0 | - | - | Stock Option (Right to Purchase) | |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.90 per share. | 08 Dec 2025 | 17,600 | 121,213 (0%) | 0% | 15.9 | 279,840 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 47.89 per share. | 08 Dec 2025 | 11,125 | 110,088 (0%) | 0% | 47.9 | 532,771 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 48.66 per share. | 08 Dec 2025 | 6,475 | 103,613 (0%) | 0% | 48.7 | 315,085 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2025 | 16,389 | 0 | - | - | Stock Option (Right to Purchase) | |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 38.21 per share. | 18 Aug 2025 | 16,389 | 103,613 (0%) | 0% | 38.2 | 626,171 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.34 per share. | 18 Aug 2025 | 16,389 | 120,002 (0%) | 0% | 21.3 | 349,741 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Aug 2025 | 4,861 | 16,389 | - | - | Stock Option (Right to Purchase) | |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 38.03 per share. | 13 Aug 2025 | 4,861 | 103,613 (0%) | 0% | 38.0 | 184,881 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.34 per share. | 13 Aug 2025 | 4,861 | 108,474 (0%) | 0% | 21.3 | 103,734 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 30.03 per share. | 20 Mar 2025 | 18,881 | 103,613 (0%) | 0% | 30.0 | 566,983 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 20 Mar 2025 | 1,927 | 122,494 (0%) | 0% | 30.0 | 57,811 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 14 Mar 2025 | 2,255 | 124,421 (0%) | 0% | 30.0 | 67,661 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 11 Mar 2025 | 15,387 | 126,676 (0%) | 0% | 30.0 | 461,672 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 11 Mar 2025 | 15,387 | 126,676 (0%) | 0% | 30.0 | 461,672 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 06 Mar 2025 | 3,295 | 144,411 (0%) | 0% | 30.0 | 98,854 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 06 Mar 2025 | 2,348 | 142,063 (0%) | 0% | 30.0 | 70,446 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 45,016 | 150,918 (0%) | 0% | 0 | Common Stock | |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 26,411 | 177,329 (0%) | 0% | 0 | Common Stock | |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.52 per share. | 10 Feb 2025 | 21,670 | 147,706 (0%) | 0% | 30.5 | 661,368 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.52 per share. | 10 Feb 2025 | 7,953 | 169,376 (0%) | 0% | 30.5 | 242,726 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 33.98 per share. | 23 May 2024 | 56,807 | 105,902 (0%) | 0% | 34.0 | 1,930,455 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.03 per share. | 23 May 2024 | 51,209 | 190,127 (0%) | 0% | 24.0 | 1,230,552 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2024 | 51,209 | 23,791 | - | - | Stock Option (Right to Purchase) | |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 33.82 per share. | 23 May 2024 | 51,209 | 138,918 (0%) | 0% | 33.8 | 1,732,093 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2024 | 23,791 | 0 | - | - | Stock Option (Right to Purchase) | |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.03 per share. | 23 May 2024 | 23,791 | 162,709 (0%) | 0% | 24.0 | 571,698 | Common Stock |
| Collegium pharma Inc | Dreyer Scott | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 36.38 per share. | 26 Feb 2024 | 9,336 | 139,582 (0%) | 0% | 36.4 | 339,601 | Common Stock |
| Collegium pharma Inc | Dreyer Scott | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 37.15 per share. | 26 Feb 2024 | 664 | 138,918 (0%) | 0% | 37.2 | 24,670 | Common Stock |
| Collegium pharma Inc | Dreyer Scott | EVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 35,000 | 146,322 (0%) | 0% | 0 | Common Stock | |
| Collegium pharma Inc | Dreyer Scott | EVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 32,286 | 178,608 (0%) | 0% | 0 | Common Stock | |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.70 per share. | 12 Feb 2024 | 19,545 | 159,063 (0%) | 0% | 33.7 | 658,667 | Common Stock |
| Collegium pharma Inc | Dreyer Scott | EVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.70 per share. | 12 Feb 2024 | 10,145 | 148,918 (0%) | 0% | 33.7 | 341,887 | Common Stock |
| Collegium pharma Inc | Dreyer Scott | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 32.28 per share. | 16 Jan 2024 | 23,560 | 111,322 (0%) | 0% | 32.3 | 760,519 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 26.70 per share. | 01 Mar 2023 | 13,324 | 134,882 (0%) | 0% | 26.7 | 355,751 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2023 | 44,275 | 147,073 (0%) | 0% | 0 | Common Stock | |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2023 | 22,459 | 169,532 (0%) | 0% | - | Common Stock | |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.75 per share. | 10 Feb 2023 | 14,529 | 155,003 (0%) | 0% | 26.8 | 388,651 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.75 per share. | 10 Feb 2023 | 6,797 | 148,206 (0%) | 0% | 26.8 | 181,820 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 27.08 per share. | 09 Jan 2023 | 10,424 | 110,208 (0%) | 0% | 27.1 | 282,282 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 27.83 per share. | 09 Jan 2023 | 7,341 | 102,867 (0%) | 0% | 27.8 | 204,300 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 28.58 per share. | 09 Jan 2023 | 69 | 102,798 (0%) | 0% | 28.6 | 1,972 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.48 per share. | 11 Jul 2022 | 594 | 120,632 (0%) | 0% | 17.5 | 10,383 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 21.61 per share. | 18 Feb 2022 | 10,559 | 121,226 (0%) | 0% | 21.6 | 228,180 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 52,500 | 128,769 (0%) | 0% | 0 | Common Stock | |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 13,675 | 142,444 (0%) | 0% | - | Common Stock | |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.63 per share. | 10 Feb 2022 | 6,643 | 135,801 (0%) | 0% | 17.6 | 117,116 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.63 per share. | 10 Feb 2022 | 4,016 | 131,785 (0%) | 0% | 17.6 | 70,802 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.05 per share. | 10 Jan 2022 | 701 | 76,269 (0%) | 0% | 19.0 | 13,354 | Common Stock |
| Collegium pharma Inc | Scott Dreyer | EVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.17 per share. | 12 Jul 2021 | 595 | 82,663 (0%) | 0% | 23.2 | 13,786 | Common Stock |